Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo: Net Profits Down 85% Due to Allowance for Potential Losses Related to Quality Problems Caused by Ranbaxy
May 15, 2012
- Otsuka HD: Pharma Sales, Profits Up; Sales of Abilify Break 400 Billion
May 15, 2012
- Eisai’s US Subsidiary Expands Exclusive Marketing Rights for Anti-Obesity Agent to 20 Countries in Americas
May 14, 2012
- Sales of Lipitor Down 6% in Fiscal Year Ended March 2012: Astellas
May 14, 2012
- Sales Force Effectiveness Japan 2012 to Be Held on July 10, 11
May 14, 2012
- Sales Up 1.6%, Vesicare Extends Global Growth: Astellas
May 14, 2012
- DSP’s Sales, Profits Down Due to Strong Yen, 1.6% Decline in Domestic Business
May 14, 2012
- DSP to Reconstruct its Business Strategy Due to Acquisition of BBI and Slow Business in North America
May 14, 2012
- The Growing Presence of Foreign-Affiliates (2)
May 14, 2012
- Struggles in US Operations Lead to 5.3% Fall in Sales, Strategic Products at Home Post 25% Rise: Shionogi
May 11, 2012
- “Figures to Look Forward to in 2013-2014” in Firm US Operations: President Teshirogi of Shionogi
May 11, 2012
- Seikagaku Licenses Domestic Marketing Rights to Kaken Pharmaceutical for Hernia Treatment SI-6603
May 11, 2012
- Executive Officer Terukazu Kato to Become New President: Tsumura
May 11, 2012
- Ono Aims to Decrease Sales Ratio of Long-Listed Drugs to 50% Level within FY2012: President Sagara
May 11, 2012
- Senior Executive Director Mitsutomo Miyashita to Be Appointed as New President: Kyorin
May 11, 2012
- Company Results for March Show Slight Fall in Drug Sales on Impact of Generics: MTPC
May 10, 2012
- Tenelia Planned to “Overwhelm Market with Power” in Alliance with Daiichi Sankyo: MTPC
May 10, 2012
- Japan Blood Products Organization to Begin Operations in October: JRCS, MTPC
May 10, 2012
- Once-Monthly Abilify Significantly Extends Time to Relapse in Adult Schizophrenia Patients: Otsuka
May 10, 2012
- Shionogi’s US Subsidiary Submits NDA for VVA Treatment Ospemifene in the US
May 10, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…